Johnson & Johnson (NYSE:JNJ) Stock Price Down 1.4% – Here’s What Happened

Johnson & Johnson (NYSE:JNJ) traded down 1.4% during mid-day trading on Thursday. The stock traded as low as $271.64 and last traded at $272.4910. 9,643,708 shares were traded during mid-day trading, an increase of 21% from the average session volume of 7,957,145 shares. The stock had previously closed at $276.32.

Key Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: The FDA granted accelerated approval to RYBREVANT FASPRO as a single-agent treatment for certain adults with recurrent or metastatic head and neck cancer after prior platinum chemotherapy and immunotherapy. J&J says the treatment is the first new option in this setting in a decade; trial data showed a 42% response rate. The approval extends the drug’s use beyond lung cancer and could broaden its commercial opportunity, though the indication is limited and accelerated approval may require confirmatory evidence. FDA approval announcement
• Positive Sentiment: J&J’s Innovative Medicine division grew third-quarter sales 7.7% to $16.76 billion, with established blockbusters and new launches more than offsetting generic competition. Continued growth despite patent-related headwinds supports the business outlook. Innovative Medicine sales report
• Neutral Sentiment: J&J was included in an article highlighting companies with a history of dividend increases and strong balance sheets. This reinforces its income-investor appeal, but the article does not identify a new company-specific dividend announcement. Dividend raisers article
• Negative Sentiment: Pomerantz LLP announced it is investigating potential claims on behalf of J&J investors. The notice does not provide details of the claims, but the investigation could add legal and reputational uncertainty. Investor investigation announcement

Analyst Upgrades and Downgrades

JNJ has been the topic of a number of recent analyst reports. Guggenheim reissued a “buy” rating and issued a $287.00 price target on shares of Johnson & Johnson in a report on Wednesday, October 7th. JPMorgan Chase & Co. lifted their price objective on shares of Johnson & Johnson from $270.00 to $285.00 and gave the stock a “neutral” rating in a report on Tuesday, September 29th. Morgan Stanley reduced their target price on Johnson & Johnson from $294.00 to $292.00 and set an “overweight” rating on the stock in a research note on Thursday, October 15th. HSBC raised their price target on Johnson & Johnson from $290.00 to $320.00 and gave the company a “buy” rating in a research report on Thursday, September 10th. Finally, Royal Bank Of Canada cut their price objective on Johnson & Johnson from $290.00 to $280.00 and set an “outperform” rating for the company in a report on Wednesday, October 14th. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and eight have given a Hold rating to the company’s stock. According to MarketBeat.com, Johnson & Johnson has an average rating of “Moderate Buy” and a consensus price target of $275.92.

Johnson & Johnson Stock Up 1.4%

The company has a quick ratio of 0.74, a current ratio of 1.02 and a debt-to-equity ratio of 0.44. The company’s fifty day moving average price is $265.91 and its 200-day moving average price is $248.30. The stock has a market capitalization of $664.76 billion, a PE ratio of 41.84, a price-to-earnings-growth ratio of 2.67 and a beta of 0.22.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, October 13th. The company reported $2.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.53 by $0.06. The business had revenue of $25.40 billion for the quarter, compared to analysts’ expectations of $25.38 billion. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. The business’s revenue for the quarter was up 5.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.80 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. Analysts forecast that Johnson & Johnson will post 11.12 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 8th. Stockholders of record on Tuesday, November 24th will be issued a $1.34 dividend. The ex-dividend date is Tuesday, November 24th. This represents a $5.36 dividend on an annualized basis and a dividend yield of 1.9%. Johnson & Johnson’s payout ratio is 81.21%.

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Jennifer Taubert sold 15,000 shares of the firm’s stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $263.36, for a total value of $3,950,400.00. Following the completion of the sale, the executive vice president owned 194,451 shares of the company’s stock, valued at $51,210,615.36. This trade represents a 7.16% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Timothy Schmid sold 33,597 shares of the firm’s stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total value of $9,230,439.78. Following the transaction, the executive vice president owned 25,447 shares in the company, valued at $6,991,308.78. The trade was a 56.90% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 0.16% of the company’s stock.

Hedge Funds Weigh In On Johnson & Johnson

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Rasp Wealth Solutions LLC increased its holdings in Johnson & Johnson by 8.2% in the third quarter. Rasp Wealth Solutions LLC now owns 2,732 shares of the company’s stock worth $723,000 after purchasing an additional 207 shares in the last quarter. MSH Capital Advisors LLC increased its stake in shares of Johnson & Johnson by 1.8% in the 3rd quarter. MSH Capital Advisors LLC now owns 22,979 shares of the company’s stock valued at $6,083,000 after acquiring an additional 415 shares in the last quarter. Ibex Wealth Advisors lifted its position in shares of Johnson & Johnson by 7.4% during the 3rd quarter. Ibex Wealth Advisors now owns 3,988 shares of the company’s stock valued at $1,056,000 after acquiring an additional 276 shares during the period. Clearwater Capital Advisors LLC lifted its position in shares of Johnson & Johnson by 1.3% during the 3rd quarter. Clearwater Capital Advisors LLC now owns 3,650 shares of the company’s stock valued at $966,000 after acquiring an additional 47 shares during the period. Finally, AlpenGlobal Capital LLC bought a new position in Johnson & Johnson during the third quarter worth $2,608,000. 69.55% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Company Profile

Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech.

Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care.

Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.